LGVN: Longeveron Inc. Stock

by  •  • Comments Off on LGVN: Longeveron Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 19.23
Enterprise Value ($M) -0.00
Book Value ($M) 21.89
Book Value / Share 1.64
Price / Book 0.88
NCAV ($M) 15.95
NCAV / Share 1.19
Price / NCAV 1.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.68
Return on Assets (ROA) -1.32
Return on Equity (ROE) -2.37

Liquidity (mrq)
Quick Ratio 7.60
Current Ratio 7.60

Balance Sheet (mrq) ($M)
Current Assets 19.62
Assets 25.56
Liabilities 3.67
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2.39
Operating Income -16.52
Net Income -15.97

Cash Flow Statement (mra) ($M)
Cash From Operations -13.87
Cash from Investing -0.64
Cash from Financing 28.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 -63.17
04-17 13G Intracoastal Capital, Llc 4.99
04-15 13D/A Hare Joshua 25.70 -86.42

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 67,808 180,981 37.47
2025-03-06 118,330 231,566 51.10
2025-03-05 31,548 110,276 28.61
2025-03-04 90,853 263,815 34.44

(click for more detail)

Similar Companies
KZR – Kezar Life Sciences, Inc. LEXX – Lexaria Bioscience Corp.
LFVN – LifeVantage Corporation LIPO – Lipella Pharmaceuticals Inc.
LIXT – Lixte Biotechnology Holdings, Inc.


Financial data and stock pages provided by
Fintel.io